Drugs / mixed amphetamine salts-extended release
mixed amphetamine salts-extended release
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT01986075 | Jan 2014 → Jan 2021 | cocaine dependence | New York State Psychiatric Institute | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT00557960 | Feb → Oct 2004 | attention deficit-hyperactivity disorder | Shire | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07650643 | Sep 2026 → May 2031 expected | attention deficit-hyperactivity disorder | Boston Children's Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT02478788 | Nov 2015 → Aug 2022 | attention deficit-hyperactivity disorder | University of Cincinnati | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mixed amphetamine salts-extended release | “This was a randomized, double-blind, placebo-controlled, crossover study of simulated driving performance with mixed amphetamine salts-extended release (MAS XR 50 mg/day (Cohort 1)” PMID 18815438 ↗ Sep 20084“Simulated driving changes in young adults with ADHD receiving mixed amphetamine salts extended release and atomoxetine.” PMID 18815438 ↗ Sep 2008 |
| Known as | MAS XR | “This study investigated the effects of 12-week mixed amphetamine salts-extended release (MAS-XR) treatment on brain functional networks and symptom changes in ADHD youth with...” PMID 40712681 ↗ Jul 20251“This was a randomized, double-blind, placebo-controlled, crossover study of simulated driving performance with mixed amphetamine salts-extended release (MAS XR 50 mg/day (Cohort 1)” PMID 18815438 ↗ Sep 2008 |
| Known as | MAS-ER | “80 mg/day of Mixed-Amphetamine Salts- Extended Release (MAS-ER) and computer -assisted CBT” NCT01986075 ↗ |